Jing Wang

Company: Eli Lilly & Co.

Job title: Director

Bio:

As an innovation-driven drug discovery scientist, I specialize in computational drug discovery. At Eli Lilly and Company, my focus is in spearheading groundbreaking research, leveraging computational methodologies to pioneer the discovery of novel therapeutic targets, particularly in the realms of peptides and antibodies. My expertise encompasses structure-based drug design, virtual screening, and sophisticated data analysis. My commitment to collaborative success is evidenced by my significant contributions to various multidisciplinary teams, driving innovations in drug discovery.

Seminars:

Panel Discussion: From Hype to Impact – Realizing the Value of AI in Biologics Design 4:15 pm

What are the current limitations and tangible successes in applying AI/ML to biologics discovery and developability? How are organizations measuring ROI from computational investments — speed, cost, accuracy, or all three? What infrastructure, culture, and talent are needed to effectively scale AI adoption across discovery and development pipelines?Read more

day: Conference Day One

Computational Approaches to Enable Challenge GPCR Agonist 3:15 pm

Apply structure-based and AI-driven methods to identify and optimize novel GPCR agonists with improved specificity Leverage predictive modeling and AI-based protein design to address limited GPCR structural data Accelerate GPCR-targeted drug discovery by integrating virtual screening with ligand-receptor interaction analysisRead more

day: Conference Day One